BUND FINANCE › Stocks › GILD
Gilead Sciences, Inc. (GILD)
NASDAQ · Stock price, chart and technical analysis
Data from Financial Modeling Prep · Nov 18, 2026, 4:00 PM New York time · may be delayed
Key stats
Quick technical read
- Price is +8.39% above its 50-day average.
- It is +19.01% above its 200-day average (long-term uptrend).
- It sits at 87% of its 52-week range (0% = low, 100% = high).
This describes price action; it is not a recommendation. The app also calculates RSI, MACD, the entry setup and 30+ indicators. How we calculate it
Fundamentals Annual
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | US$27.3B | US$27.3B | US$27.1B | US$28.8B | US$29.4B |
| Net income | US$6.2B | US$4.6B | US$5.7B | US$480.0M | US$8.5B |
| EPS (diluted) | 4.93 | 3.64 | 4.50 | 0.38 | 6.78 |
| Gross margin | 75.8% | 79.3% | 76.0% | 78.3% | 78.8% |
| Operating margin | 36.3% | 26.9% | 28.1% | 5.8% | 34.0% |
| Net margin | 22.8% | 16.8% | 20.9% | 1.7% | 28.9% |
| Free cash flow | US$10.8B | US$8.3B | US$7.4B | US$10.3B | US$9.5B |
| Total debt | US$26.7B | US$25.2B | US$25.0B | US$26.7B | US$24.9B |
| Cash | US$5.3B | US$5.4B | US$6.1B | US$10.0B | US$7.6B |
Compound annual growth: revenue 1.9% · net income 8.1% (4 years).
Valuation: today, its history and its sector
| Today | 5-year average | Sector median (Healthcare) | |
|---|---|---|---|
| P/E | — | 63.4x | 27.1x |
| EV / EBITDA | 177.5x | 15.6x | 16.5x |
| Operating margin | 37.8% | — | 3.6% |
| Net margin | -12.5% | — | -0.0% |
| Debt / equity | 2.95 | — | 0.58 |
Source: annual financial statements from Financial Modeling Prep. “Today” uses the current price and the last 4 quarters. The sector median uses U.S. companies above US$300M market cap. A multiple above or below its history or sector is not a recommendation.
About Gilead Sciences, Inc.
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vo…
Other stocks on BUND FINANCE
Not financial advice. BUND FINANCE publishes general information for educational purposes. Investing involves risk, including loss of capital. Legal notice